Amalgamated Bank increased its stake in Davita Inc (NYSE:DVA) by 9.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 19,246 shares of the company’s stock after acquiring an additional 1,698 shares during the period. Amalgamated Bank’s holdings in Davita were worth $1,391,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors also recently made changes to their positions in DVA. FDx Advisors Inc. raised its stake in shares of Davita by 28.6% in the third quarter. FDx Advisors Inc. now owns 46,836 shares of the company’s stock valued at $2,782,000 after acquiring an additional 10,427 shares in the last quarter. Migdal Insurance & Financial Holdings Ltd. acquired a new stake in shares of Davita in the third quarter valued at $154,000. Meag Munich Ergo Kapitalanlagegesellschaft MBH raised its stake in shares of Davita by 1,987.3% in the third quarter. Meag Munich Ergo Kapitalanlagegesellschaft MBH now owns 41,746 shares of the company’s stock valued at $2,448,000 after acquiring an additional 39,746 shares in the last quarter. Rhumbline Advisers raised its stake in shares of Davita by 4.4% in the third quarter. Rhumbline Advisers now owns 321,155 shares of the company’s stock valued at $19,073,000 after acquiring an additional 13,471 shares in the last quarter. Finally, Oak Associates Ltd. OH raised its stake in shares of Davita by 3.8% in the third quarter. Oak Associates Ltd. OH now owns 192,185 shares of the company’s stock valued at $11,414,000 after acquiring an additional 6,990 shares in the last quarter. Institutional investors and hedge funds own 85.80% of the company’s stock.
Shares of DVA traded down $2.15 during midday trading on Monday, reaching $63.79. 2,434,508 shares of the stock were exchanged, compared to its average volume of 1,571,323. The company has a debt-to-equity ratio of 1.87, a quick ratio of 2.82 and a current ratio of 2.88. Davita Inc has a twelve month low of $52.51 and a twelve month high of $80.71. The stock has a market capitalization of $12,001.08, a P/E ratio of 19.21, a price-to-earnings-growth ratio of 0.95 and a beta of 1.09.
Davita (NYSE:DVA) last posted its earnings results on Tuesday, February 13th. The company reported $0.92 EPS for the quarter, missing the Zacks’ consensus estimate of $0.94 by ($0.02). Davita had a return on equity of 12.86% and a net margin of 4.65%. The firm had revenue of $2.78 billion for the quarter, compared to analyst estimates of $3.90 billion. During the same quarter last year, the firm posted $0.98 EPS. equities research analysts forecast that Davita Inc will post 4.15 EPS for the current fiscal year.
In related news, insider James K. Hilger sold 3,572 shares of the firm’s stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $78.95, for a total transaction of $282,009.40. Following the transaction, the insider now owns 33,649 shares of the company’s stock, valued at $2,656,588.55. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 2.00% of the company’s stock.
Several brokerages have recently issued reports on DVA. SunTrust Banks reiterated a “hold” rating and issued a $80.00 price objective on shares of Davita in a research note on Wednesday, February 14th. Robert W. Baird set a $97.00 price target on Davita and gave the company a “buy” rating in a research note on Tuesday, February 13th. Bank of America restated a “buy” rating and issued a $92.00 price target (up from $85.00) on shares of Davita in a research note on Thursday, January 11th. Zacks Investment Research upgraded Davita from a “strong sell” rating to a “hold” rating in a research note on Tuesday, January 2nd. Finally, TheStreet upgraded Davita from a “c” rating to a “b-” rating in a research note on Thursday, January 4th. Two analysts have rated the stock with a sell rating, five have given a hold rating, four have issued a buy rating and two have assigned a strong buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $79.30.
TRADEMARK VIOLATION NOTICE: This news story was first published by Enterprise Leader and is the property of of Enterprise Leader. If you are viewing this news story on another publication, it was illegally stolen and republished in violation of U.S. & international copyright law. The legal version of this news story can be read at https://theenterpriseleader.com/2018/04/02/davita-inc-nysedva-holdings-boosted-by-amalgamated-bank.html.
Davita Company Profile
DaVita Inc, formerly DaVita HealthCare Partners Inc, operates two divisions: DaVita Kidney Care (Kidney Care) and DaVita Medical Group (DMG). The Kidney Care division consists of its the United States dialysis and related lab services, its ancillary services and strategic initiatives, including its international operations, and its corporate administrative support.
Receive News & Ratings for Davita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Davita and related companies with MarketBeat.com's FREE daily email newsletter.